Scholars Central

Search Scholars Central

Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.

Advanced searchHide advanced search

In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:

Years

1–25 of 830 articles for biosimilars

Then save them, add them to a collection or cite them together.
  1. Conference abstract · 10 Aug 2017

    Biosimilars: Challenges in safety and risk management

    Advances in biotechnology have ensured a world of opportunities for biosimilars to enter the market and serve the needs of patients in a cost-effective manner. However, Pharmacovigilance and risk ... management for…

  2. Conference abstract · 20 Jul 2017

    Global Status of Biosimilars & Prospects in Asia

    Almost one decade back the first biosimilar was launched in Europe. Now they have 15 biosimilars and all are well accepted since high price branded biologics were tough to reach ... many patients. Recently biosimilars…

  3. Conference abstract · 24 Oct 2018

    How to start a Biosimilar development: A risk based approach

    With the big success of biologicals and the experience in generics, the biosimilar development was born. In Europe, the first biosimilars were already approved in the 2006 and since then ... especially in Europe…

  4. Conference abstract · 27 Jun 2016

    Biosimilar Development Cost: Role of Analytics

    biosimilar product is a biological product that is approved based on showing that it is highly similar to the reference product, with no clinically meaningful differences in terms of safety ... efficacy and quality from…

  5. Conference abstract · 24 Oct 2018

    The end of clinical trials in biosimilars development

    regulatory guidance, one should discuss the relevance of the current clinical development model for biosimilars and raise the following long-term questions: is it the end of clinical trials ... biosimilar development,”…

  6. Conference abstract · 24 Oct 2018

    Understanding the market access landscape for Biosimilars

    Biosimilars were touted as a payer’s tool to gain savings in specialty markets, but a recent survey by Avalere of the top 25 payers in the U.S. (about ... million covered lives) using publicly available coverage…

  7. Conference abstract · 9 Nov 2017

    Biosimilars in the UK’s NHS: Attitudes, appetites and acceptance

    ready for the biosimilars boom? to most, biosimilars are a no-brainer. But as with anything new, there are early adopters and sceptics. The NIHR CRN is an independent, government ... insight. The NIHR CRN can report…

  8. Conference abstract · 19 Oct 2016

    Emerging biosimilars in the USA – quo vadis

    While the US biosimilar market has lagged behind Europe for almost a decade due to delays concerning the release of specific guidelines by the FDA, the market is poised ... Remicade, and Humira will lose patent…

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels